Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Water soluble extract of Rhizoma Polygonati Odorati (RPO) was studied for its hypoglycemic effect in diabetic mice and rats. Results showed that RPO significantly lowered hyperglycemia caused by starch loading in both normal and diabetic mice. Four week's administration with RPO reduced fasting blood glucose, decreased glycosylated hemoglobin (GHb), and improved the glucose tolerance in diabetic mice. In diabetic rats complicated with hyperlipemia, RPO prevented and reduced both hyperglycemia and hypertriglyceridemia. The results support the view that RPO may influence glucose or carbohydrate metabolism of diabetic animals in many ways including inhibiting the activity of alpha-glucosidase in digestive canal, and improving the metabolism of glucose and triglyceride.
...
PMID:Hypoglycemic effects of aqueous extract of Rhizoma Polygonati Odorati in mice and rats. 1127 22

This study was designed to monitor the metabolic differences after feeding starch, galactose and fructose diets with adequate or marginal copper levels to normal male rats over a period of 9-21 months. Two hundred and forty-five weanling male Sprague-Dawley rats weighing approximately 50-60 g were randomly divided into one of the eight dietary groups. All diets were either Cu marginal (1.5 &mgr;g/g diet) or adequate (5-6 &mgr;g/g) with 627 carbohydrate (g/kg diet) as starch; 500 galactose and 127 starch; 500 fructose and 127 starch; or 400 galactose and 227 fructose. Glycated hemoglobin, ceruloplasmin oxidase activity, hematocrit, and plasma glucose, cholesterol, and triglyceride were measured in 72 rats after nine months. Galactose-fed rats had the lowest (P < 0.0001) body weights. Severe mortality rates were found in galactose-fructose-marginal Cu-fed rats. Marginal Cu deficiency significantly (P < 0.0001) reduced hepatic copper and increased hepatic Fe in all carbohydrate groups. Ceruloplasmin activity of the rats fed the marginal Cu and fructose-containing diets declined to undetectable levels and plasma cholesterol levels increased. Glycated hemoglobin was significantly (P < 0.001) increased in the galactose-fed rats compared to fructose or starch-fed rats regardless of dietary copper concentration. The data suggest that dietary galactose and fructose exacerbate effects of long term marginal Cu intake including hypertrophy of liver, heart and kidney, hyperlipidemia, and increased mortality.
...
PMID:Effects of dietary galactose and fructose on rats fed diets marginal or adequate in copper for 9-21 months. 1144 91

A pandemic of obesity is contributing importantly to the prevalence of the metabolic syndrome characterized by hypertension, insulin resistance, and hyperlipidemia. In turn, the metabolic syndrome is contributing to vascular disease and the accelerating epidemic of chronic renal failure. Currently, pharmacological approaches to attenuate obesity and its cardiovascular/renal sequelae are limited. The purpose of this study was to determine the effects of 2-hydroxyestradiol, a metabolite of 17beta-estradiol with minimal estrogenic activity, on the development of obesity, the metabolic syndrome, and heart, vascular, and renal dysfunction in obese ZSF1 rats, a well-characterized genetic model of obesity and the metabolic syndrome with concomitant heart, vascular, and kidney disease. ZSF1 rats were treated, beginning at 12 weeks of age, for 26 weeks with vehicle or 2-hydroxyestradiol (10 microg/kg/h). At baseline and after 24 weeks of treatment, animals were placed in metabolic cages, and food intake, water intake, urine output, and urinary excretion of proteins and glucose were determined. Next, in fasting animals, plasma cholesterol was measured, an oral glucose tolerance test was conducted, and total glycated hemoglobin levels were determined. At the end of the study, animals were anesthetized and instrumented for assessment of heart performance, renal hemodynamics, and mesenteric vascular reactivity. 2-Hydroxyestradiol attenuated the development of obesity and improved endothelial function, decreased nephropathy, decreased the severity of diabetes, lowered arterial blood pressure, and reduced plasma cholesterol. 2-Hydroxyestradiol may be an important lead for the development of safe and effect drugs to attenuate obesity and its metabolic, vascular, and renal sequelae.
...
PMID:2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. 1171 85

BACKGROUND: High doses of niacin have been shown to impair glucose control in patients with non--insulin-dependent diabetes mellitus (NIDDM). We undertook a study to determine if low-dose niacin has a similar effect. METHODS: Patients with stable NIDDM and hyperlipidemia underwent a 2-month observation phase where diet and diabetes medication were unchanged. Fasting blood sugar was determined every 2 weeks, and hemoglobin A(1c) and lipid profile was obtained at week 8. Patients then received niacin 500 mg three times daily for 2 months with fasting blood sugar measured every 2 weeks and hemoglobin A(1c) and lipid profile determined at week 16. Statistical analysis was performed using a t-test for related groups. RESULTS: Six of nine patients completed the protocol. Mean fasting blood sugar was statistically higher during niacin therapy versus baseline (131 mg/dL plus minus 27 vs. 161 mg/dL plus minus 40, p < 0.05). Two patients had an increase in fasting blood sugar exceeding 200 mg/dL. No change was noted in hemoglobin A(1c). There was a trend in a decrease in total cholesterol, low-density lipoprotein and triglyceride. High-density lipoprotein was statistically higher after niacin therapy. CONCLUSION: Low-dose niacin increases fasting blood sugar in patients with stable NIDDM.
...
PMID:Effect of Low-Dose Niacin on Glucose Control in Patients with Non--Insulin-Dependent Diabetes Mellitus and Hyperlipidemia. 1186 4

Stabilized rice bran (SRB), a source of complex carbohydrates, tocols, gamma-oryzanols, and polyphenols, was treated with carbohydrases and heat to yield two fractions, rice bran water solubles (RBWS), and rice bran fiber concentrates (RBFC). Stabilized rice bran and its fractions were fed for 60 days to insulin-dependent and noninsulin-dependent diabetes mellitus (IDDM = Type I and NIDDM = Type II) subjects to determine possible effects on serum hemoglobin, carbohydrate and lipid parameters. The Type I subjects (n = 22, 26, and 20) fed Stabilized rice bran, rice bran water solubles, and rice bran fiber concentrates plus AHA Step-1 diet reduced glycosylated hemoglobin 1%, 11%, and 10%, respectively. The fasting serum glucose levels were also reduced significantly (P < 0.01) with stabilized rice bran (9%), rice bran water solubles (29%), and rice bran fiber concentrates (19%).The Type II subjects (n = 31, and 26) fed rice bran water solubles and rice bran fiber concentrates plus AHA Step-1 diet had decreased levels of glycosylated hemoglobin (15% and 11%) and fasting glucose (33% and 22%; P < 0.001), respectively. Serum insulin levels were increased (4%) with rice bran water solubles in both types of diabetes. The reduction of glycosylated hemoglobin and a slight increase in insulin levels indicate that consumption of rice bran water solubles can control blood glucose levels in human diabetes. Serum total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides levels were reduced with rice bran fiber concentrates in the Type I (10, 16, 10, 7%) and Type II groups (12, 15, 10, 8%), respectively. These results indicate that rice bran water solubles significantly reduces hyperglycemia (P < 0.01), whereas rice bran fiber concentrates reduces hyperlipidemia (P < 0.05) in both types of diabetes. Therefore, these natural products can be used as nutritional supplements for the control of both types of diabetes mellitus in humans.
...
PMID:Effects of stabilized rice bran, its soluble and fiber fractions on blood glucose levels and serum lipid parameters in humans with diabetes mellitus Types I and II. 1189 82

We developed a latex turbidometric immunoassay(LTIA) for elastase 1. The precisions were 1.0-2.8% intra-run and 1.2-2.9% inter-day. The dilution test showed good linearity between 80-4000 ng/dl. There was interference by bilirubin, hemoglobin, lipemia or rheumatoid factor. Serum and plasma elastase 1 measured by LTIA(y) showed significant correlations with those by RIA(x) (serum: y = 0.98x--18, r = 0.980, n = 64, plasma: y = 0.96x--19, r = 0.976, n = 61). It was confirmed that the values were elevated in patients with pancreatic disease compared to the normal level. These results demonstrate that the determination of elastase 1 in plasma or serum by this method is useful, simple and time-saving, when compared with that by RIA.
...
PMID:[Determination of elastase 1 in plasma or serum by latex turbidometric immunoassay with automatic analyzer]. 1201 17

BACKGROUND: The purpose of the investigation presented here was to study the effects of insulin therapy in type 2 diabetes mellitus (type 2 DM) not only on glycemic control but also on other components of the metabolic syndrome, including lipid metabolism, blood pressure, and body weight. METHODS: Twelve patients with type 2 DM were studied before and after replacement of sulphonylurea treatment with insulin for 4 months. RESULTS: Insulin therapy resulted in a significant decrease in fasting glucose levels by 26%; glycated hemoglobin decreased by 17% and fructosamine values by 19%. With insulin treatment, fasting plasma triglyceride levels decreased by 28% and total HDL cholesterol and HDL(3) cholesterol increased by 17 and 11%, respectively. Low-density lipoprotein (LDL) cholesterol showed no significant change. The magnitude of postprandial lipemia after ingestion of a standard fatty meal decreased by 38%. Insulin treatment was also accompanied by a 21% increase in lipoprotein lipase (LPL) activity in postheparin plasma and by a 20% increase in cholesteryl ester transfer protein (CETP) activity. Hepatic lipase activity was not changed significantly with insulin. Mean BMI decreased from 28.5+/-4.2 to 28.0+/-3.1 kg/m(2) (P=0.02), which is in keeping with the finding that peripheral insulin levels did not increase and which can be explained by the fact that the insulin regimen was combined with dietary counseling. Accordingly, blood pressure showed no significant change. CONCLUSION: Our study demonstrates that judicious replacement of sulfonylurea treatment with insulin therapy, together with dietary counseling, can result in a simultaneous improvement in the major stigmata of the metabolic syndrome, i.e. a significant improvement in glycemic control and lipid metabolism without unfavorable effects on body weight and blood pressure.
...
PMID:Insulin improves fasting and postprandial lipemia in type 2 diabetes. 1206 22

A homogenous enzyme immunoassay (EIA) for measurement of serum thyroxine (T4) concentration was evaluated for use with canine and feline serum. The EIA method was linear from 0 to 150 nmol T4/L for human serum, 0 to 94 nmol T4/L for feline serum and 10 to 60 nmol T4/L for canine serum. Intra- and interassay precision studies yielded coefficients of variation </= 8% using single point measurements. Method comparison studies gave close agreement between radioimmunoassay (RIA) and EIA results. Correlation coefficients (r values) were 0.88 and 0.97 for canine and feline samples respectively, after application of species-specific factors to correct the calibrator values assigned for human serum samples. The EIA showed no interference from hemolysis at hemoglobin concentrations </= 20 g/L or from moderate lipemia. Highly lipemic specimens could be tested after centrifugation to clarify the sample. The EIA showed less interference from autoantibodies to T4 than the RIA method. The EIA method allows automation of T4 testing in a veterinary hospital or laboratory, and can be integrated with the routine clinical chemistry panel.
...
PMID:Evaluation of an automated, homogeneous enzyme immunoassay for serum thyroxine measurement in dog and cat serum. 1207 33

Low-glycemic index diets are associated with a wide range of benefits when followed on a chronic basis. The chronic effects, however, of the substitution of 1 meal per day are not well known in diabetic subjects. Therefore, we aimed to evaluate whether the chronic use of a low-glycemic index breakfast (low-GIB) rich in low-GI carbohydrates and a modest amount of soluble fibers could have an effect on lipemia at a subsequent lunch, and improve glucose and lipid metabolism in men with type 2 diabetes. A total of 13 men with type 2 diabetes were randomly allocated in a double-blind cross-over design to a 4-week daily intake of a low-GI versus a high-GI breakfast separated by a 15-day washout interval. The low-GI breakfast was composed of whole grain bread and muesli containing 3 g beta-glucan from oats. Low-GIB induced lower postprandial plasma glucose peaks than the high-GIB at the beginning (baseline, P <.001) and after the 4-week intake (P <.001). The incremental area under the plasma glucose curve was also lower (P <.001, P <.01, baseline, and 4 weeks, respectively). There was no effect on fasting plasma glucose, insulin, fructosamine, or glycosylated hemoglobin (HbA(1c)). Fasting plasma cholesterol, as well as the incremental area under the cholesterol curve, were lower (P <.03, P <.02) after the 4-week low-GIB period than after the high-GIB period. Apolipoprotein B (apo B) was also decreased by the 4-week low-GIB. There was no effect of the low-GI breakfast on triacylglycerol excursions or glucose and insulin responses at the second meal. The high-GIB, however, tended to decrease the amount of mRNA of leptin in abdominal adipose tissue, but had no effect on peroxisome proliferator-activated receptor gamma (PPARgamma) and cholesterylester transfer protein (CETP) mRNA amounts. In conclusion, the intake of a low-GI breakfast containing a modest amount (3 g) of beta-glucan for 4 weeks allowed good glycemic control and induced low plasma cholesterol levels in men with type 2 diabetes. The decrease in plasma cholesterol associated with low-GI breakfast intake may reduce the risk of developing cardiovascular complications in subjects with type 2 diabetes.
...
PMID:Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. 1207 24

Oxidative modification of lipoproteins in vessel walls plays a key role in atherogenesis. Patients with glycogen storage disease type Ia (GSD Ia) do not develop premature atherosclerosis despite severe hyperlipidemia. We analyzed antioxidative defense and oxidative stress in plasma and serum of patients with GSD Ia (n = 17) compared to patients with type I diabetes mellitus (DMI, n = 17), familial hypercholesterolemia (FH, n = 18), and healthy controls (n = 20). We measured the total radical-trapping antioxidant parameter (TRAP), single antioxidants (sulfhydryl groups, uric acid, vitamin C, alpha-tocopherol, coenzyme Q10), malondialdehyde, oxidized low density lipoprotein (LDL) antibodies, lipid profile [cholesterol, triglyceride, lipoprotein (a)], homocysteine, and hemoglobin (Hb)A(1C). TRAP levels were elevated in the GSD Ia group (p <.01) and correlated with elevated uric acid levels (r = 0.72, p =.001). None of the other plasma antioxidants correlated with TRAP levels. DMI patients showed decreased sulfhydryl groups (p <.01) and a reduced ubiquinol-10 fraction (p <.01). Malondialdehyde (p <.001) and oxidized LDL autoantibodies (p <.05) were increased in the diabetic group. In FH patients, parameters of oxidative stress and TRAP did not differ from controls. We conclude that in GSD Ia an increased antioxidative defense in plasma may protect against lipid peroxidation and thus against premature atherosclerosis. Furthermore, we demonstrated that in DMI increased oxidative mechanisms are already present in childhood.
...
PMID:Plasma antioxidants in pediatric patients with glycogen storage disease, diabetes mellitus, and hypercholesterolemia. 1208 88


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>